---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-132559"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:09:54.641322+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal posts Q1 net loss of ~$147.5M as Rezdiffra launch ramps up

## Summary
- Rezdiffra received FDA accelerated approval on March 14, 2024; first shipments to patients began in April.
- No Q1 revenue; operating expenses of $152.0M (up 94% YoY) due to commercial preparation and headcount.
- Cash, cash equivalents and marketable securities of $1.1B after $690M gross proceeds from public offering.
- Appointed Mardi C. Dier as CFO on February 28, 2024.
- European MAA for resmetirom validated and under EMA review.

## SEC filing metadata
- accession: 0001193125-24-132559
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/0001193125-24-132559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/d828444d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-132559
- JSON: https://secwatch.observer/filing/0001193125-24-132559.json
- Plain text: https://secwatch.observer/filing/0001193125-24-132559.txt

## Key facts
- Earnings Releases
  MADRIGAL PHARMACEUTICALS, INC. reported financial results for first-quarter 2024.
  - Period: first-quarter 2024
  - Result: reported results
  source text: On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/0001193125-24-132559-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.